Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- ARDS, Human
- COVID-19
- SARS CoV-2 Infection
- Severe covid19
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
PRP decreases IL-1?, IL-6, IL-8, and TNF? inflammatory genes expression while also reduces IL-1? and TNF? inflammatory cytokines production. PRP has also been showed to contain interleukin 1 receptor antagonist (IL-1RA), an anti-inflammatory cytokines that suppress IL-6 secretion.
PRP decreases IL-1?, IL-6, IL-8, and TNF? inflammatory genes expression while also reduces IL-1? and TNF? inflammatory cytokines production. PRP has also been showed to contain interleukin 1 receptor antagonist (IL-1RA), an anti-inflammatory cytokines that suppress IL-6 secretion.
Tracking Information
- NCT #
- NCT04715360
- Collaborators
- Koja Regional Public Hospital
- Investigators
- Principal Investigator: Louis Martin Christoffel, MD Koja Regional Public Hospital